[go: up one dir, main page]

MX2014001489A - Composicion para la estimulacion ovarica controlada. - Google Patents

Composicion para la estimulacion ovarica controlada.

Info

Publication number
MX2014001489A
MX2014001489A MX2014001489A MX2014001489A MX2014001489A MX 2014001489 A MX2014001489 A MX 2014001489A MX 2014001489 A MX2014001489 A MX 2014001489A MX 2014001489 A MX2014001489 A MX 2014001489A MX 2014001489 A MX2014001489 A MX 2014001489A
Authority
MX
Mexico
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
MX2014001489A
Other languages
English (en)
Other versions
MX348981B (es
Inventor
Joan-Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2014001489A publication Critical patent/MX2014001489A/es
Publication of MX348981B publication Critical patent/MX348981B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a preparaciones que incluyen una FSH, por ejemplo una FSH recombinante, para el uso en el tratamiento de la infertilidad. La figura más representativa de la invención es la número 8.
MX2014001489A 2011-08-08 2012-08-08 Composicion para la estimulacion ovarica controlada. MX348981B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176803 2011-08-08
PCT/EP2012/065507 WO2013020996A1 (en) 2011-08-08 2012-08-08 Composition for controlled ovarian stimulation

Publications (2)

Publication Number Publication Date
MX2014001489A true MX2014001489A (es) 2014-04-25
MX348981B MX348981B (es) 2017-07-06

Family

ID=46785372

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2014001489A MX348981B (es) 2011-08-08 2012-08-08 Composicion para la estimulacion ovarica controlada.
MX2017004482A MX381278B (es) 2011-08-08 2012-08-08 Composición para la estimulación ovárica controlada.
MX2020010991A MX2020010991A (es) 2011-08-08 2014-02-06 Composicion para la estimulacion ovarica controlada.
MX2024008825A MX2024008825A (es) 2011-08-08 2014-02-06 Composicion para la estimulacion ovarica controlada.
MX2024008826A MX2024008826A (es) 2011-08-08 2014-02-06 Composicion para la estimulacion ovarica controlada.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2017004482A MX381278B (es) 2011-08-08 2012-08-08 Composición para la estimulación ovárica controlada.
MX2020010991A MX2020010991A (es) 2011-08-08 2014-02-06 Composicion para la estimulacion ovarica controlada.
MX2024008825A MX2024008825A (es) 2011-08-08 2014-02-06 Composicion para la estimulacion ovarica controlada.
MX2024008826A MX2024008826A (es) 2011-08-08 2014-02-06 Composicion para la estimulacion ovarica controlada.

Country Status (30)

Country Link
US (5) US9694052B2 (es)
EP (9) EP3195875B1 (es)
JP (5) JP6161609B2 (es)
KR (8) KR20250126867A (es)
CN (2) CN103732243A (es)
AR (1) AR087476A1 (es)
AU (3) AU2012293647B2 (es)
BR (2) BR122020001644B1 (es)
CA (1) CA2844282A1 (es)
CY (1) CY1117214T1 (es)
DK (8) DK4005588T5 (es)
ES (8) ES2742163T3 (es)
FI (2) FI4005588T3 (es)
HR (8) HRP20240420T1 (es)
HU (8) HUE044610T2 (es)
IL (2) IL300380A (es)
JO (1) JO3092B1 (es)
LT (7) LT3566712T (es)
MX (5) MX348981B (es)
PL (8) PL2821080T3 (es)
PT (6) PT3395357T (es)
RS (8) RS54561B1 (es)
RU (2) RU2739037C3 (es)
SA (1) SA112330762B1 (es)
SI (8) SI3646881T1 (es)
SM (1) SMT201600038B (es)
TR (2) TR201911269T4 (es)
TW (2) TWI555530B (es)
WO (1) WO2013020996A1 (es)
ZA (2) ZA201400952B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2016102436A1 (en) * 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
ES2784625T3 (es) * 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
CN115028675A (zh) 2015-06-26 2022-09-09 辉凌公司 纯化和/或病毒灭活的方法
BR112018003455A2 (pt) * 2015-09-17 2018-09-25 Glycotope Gmbh composição ou composição farmacêutica e uso da composição
IL311335A (en) * 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility
KR20200045543A (ko) 2017-09-01 2020-05-04 훼링 비.브이. 조절된 난소 자극용 조성물
DK3787667T3 (da) 2018-04-30 2025-06-16 Ferring Bv Sammensætning til kontrolleret ovariestimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US11576920B2 (en) 2019-03-18 2023-02-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN110841060A (zh) * 2019-11-21 2020-02-28 上海交通大学 Choriogonadotropin alfa在治疗多囊卵巢综合征中的应用
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
KR20240167660A (ko) 2022-04-01 2024-11-27 훼링 비.브이. 불임의 치료를 위한 혼합 프로토콜
EP4531895A1 (en) 2022-05-26 2025-04-09 Ferring B.V. Compositions and methods for treatment of infertility in males
US20250367262A1 (en) 2022-07-08 2025-12-04 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
EP1074265A1 (en) * 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
JP2005515974A (ja) 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US8501719B2 (en) * 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
DE102010007984B4 (de) 2010-02-15 2012-01-26 Hochland Ag Form- und Kühlvorrichtung für eine fließfähige, aufgeschmolzene Lebensmittelmasse
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
SI2621517T2 (sl) * 2010-09-29 2023-11-30 Ferring B.V. Sestavek za uporabo pri zdravljenju neplodnosti
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
TW201309322A (zh) 2013-03-01
JP2019077693A (ja) 2019-05-23
PT3395357T (pt) 2019-08-27
PL2741763T3 (pl) 2016-07-29
EP3195875B1 (en) 2018-07-25
WO2013020996A1 (en) 2013-02-14
LT3395357T (lt) 2019-08-26
HRP20190023T1 (hr) 2019-02-22
ZA201506382B (en) 2017-01-25
HRP20210722T1 (hr) 2021-06-11
HRP20230607T1 (hr) 2023-09-29
EP4005588A1 (en) 2022-06-01
SI3395357T1 (sl) 2019-09-30
SI3756681T1 (sl) 2023-08-31
RS57897B1 (sr) 2019-01-31
PL3646881T3 (pl) 2021-11-02
PL3566712T3 (pl) 2021-07-12
ES2692774T3 (es) 2018-12-05
HUE041769T2 (hu) 2019-05-28
US20200345814A1 (en) 2020-11-05
SI3646881T1 (sl) 2021-08-31
KR102499969B1 (ko) 2023-02-14
CY1117214T1 (el) 2017-04-05
ES2742163T3 (es) 2020-02-13
RS64328B1 (sr) 2023-08-31
ES2977682T3 (es) 2024-08-28
EP4306174A3 (en) 2024-04-10
PL2821080T3 (pl) 2019-04-30
ZA201400952B (en) 2022-03-30
KR20200121918A (ko) 2020-10-26
PT3646881T (pt) 2021-06-02
RS61843B1 (sr) 2021-06-30
HK1204923A1 (en) 2015-12-11
KR20190100449A (ko) 2019-08-28
JP7309660B2 (ja) 2023-07-18
US9694052B2 (en) 2017-07-04
BR122020001644B1 (pt) 2022-08-02
HRP20240420T1 (hr) 2024-06-21
EP3756681B1 (en) 2023-05-03
ES2562648T3 (es) 2016-03-07
KR20210099162A (ko) 2021-08-11
EP3646881A1 (en) 2020-05-06
RU2739037C2 (ru) 2020-12-21
KR102014469B1 (ko) 2019-08-26
EP3646881B1 (en) 2021-04-28
ES2704878T3 (es) 2019-03-20
EP2821080A1 (en) 2015-01-07
KR102353144B1 (ko) 2022-01-18
RS54561B1 (sr) 2016-06-30
TW201716082A (zh) 2017-05-16
HUE040058T2 (hu) 2019-02-28
SA112330762B1 (ar) 2015-10-08
US12478660B2 (en) 2025-11-25
JO3092B1 (ar) 2017-03-15
RS59107B1 (sr) 2019-09-30
DK3756681T3 (da) 2023-07-31
DK3566712T3 (da) 2021-04-19
MX2020010991A (es) 2020-11-09
JP6500050B2 (ja) 2019-04-10
KR20210143934A (ko) 2021-11-29
LT3756681T (lt) 2023-07-25
EP4306174A2 (en) 2024-01-17
LT2821080T (lt) 2019-01-10
RU2613324C3 (ru) 2021-06-09
SI2821080T1 (sl) 2019-01-31
JP6161609B2 (ja) 2017-07-12
MX348981B (es) 2017-07-06
SMT201600038B (it) 2016-02-25
ES2884947T3 (es) 2021-12-13
PL3756681T3 (pl) 2023-08-21
IL230696B1 (en) 2023-03-01
RS58198B1 (sr) 2019-03-29
LT3566712T (lt) 2021-03-10
HUE053716T2 (hu) 2021-07-28
IL230696A0 (en) 2014-03-31
HUE027674T2 (en) 2016-11-28
DK4005588T5 (da) 2024-08-05
RU2613324C2 (ru) 2017-03-15
DK4005588T3 (da) 2024-04-29
HUE054312T2 (hu) 2021-08-30
PL3395357T3 (pl) 2019-11-29
JP2023134561A (ja) 2023-09-27
HUE062640T2 (hu) 2023-11-28
MX2024008825A (es) 2024-07-25
CN107281470A (zh) 2017-10-24
LT3646881T (lt) 2021-05-25
AU2018203222A1 (en) 2018-05-24
HUE066158T2 (hu) 2024-07-28
ES2871405T3 (es) 2021-10-28
KR102111514B1 (ko) 2020-05-18
IL230696B2 (en) 2023-07-01
EP3395357A1 (en) 2018-10-31
AU2012293647A1 (en) 2014-02-27
AU2018203222B2 (en) 2020-03-12
TR201911269T4 (tr) 2019-08-21
JP6718951B2 (ja) 2020-07-08
KR20190140098A (ko) 2019-12-18
RU2014102924A (ru) 2015-09-20
EP3195875A1 (en) 2017-07-26
RS65485B1 (sr) 2024-05-31
EP2741763B1 (en) 2015-11-18
RS61672B1 (sr) 2021-04-29
DK3195875T3 (en) 2018-11-12
KR20140054191A (ko) 2014-05-08
EP4005588B1 (en) 2024-02-07
HK1198005A1 (zh) 2015-03-06
IL300380A (en) 2023-04-01
BR112014002884A2 (pt) 2017-02-21
AU2012293647B2 (en) 2016-10-06
KR20250126867A (ko) 2025-08-25
LT3195875T (lt) 2018-11-12
PT4005588T (pt) 2024-04-24
US11291708B2 (en) 2022-04-05
ES2950911T3 (es) 2023-10-16
US10624953B2 (en) 2020-04-21
TWI555530B (zh) 2016-11-01
RU2017106756A (ru) 2019-01-23
EP3566712A1 (en) 2019-11-13
PT3195875T (pt) 2018-10-31
HRP20160145T1 (hr) 2016-04-08
JP2017141253A (ja) 2017-08-17
FI3756681T3 (fi) 2023-07-28
HUE044610T2 (hu) 2019-11-28
NZ620369A (en) 2015-12-24
SI4005588T1 (sl) 2024-06-28
RU2017106756A3 (es) 2020-07-09
US20220370567A1 (en) 2022-11-24
JP2014522871A (ja) 2014-09-08
HRP20181639T1 (hr) 2018-12-14
PL4005588T3 (pl) 2024-06-10
MX381278B (es) 2025-03-12
AU2016273925A1 (en) 2017-01-12
HRP20210277T1 (hr) 2021-04-02
KR20230024442A (ko) 2023-02-20
DK3646881T3 (da) 2021-07-26
TWI657822B (zh) 2019-05-01
DK2821080T3 (en) 2019-01-28
EP3566712B1 (en) 2021-01-27
HRP20191437T1 (hr) 2019-11-15
DK3395357T3 (da) 2019-08-19
CN103732243A (zh) 2014-04-16
EP3395357B1 (en) 2019-05-15
EP2741763A1 (en) 2014-06-18
EP2821080B1 (en) 2018-10-10
MX2024008826A (es) 2024-07-25
AU2016273925B2 (en) 2018-03-15
LT4005588T (lt) 2024-03-25
SI3195875T1 (sl) 2018-11-30
RU2739037C3 (ru) 2021-09-08
DK2741763T3 (da) 2016-02-15
SI3566712T1 (sl) 2021-04-30
DK3756681T5 (da) 2024-08-26
US20180028620A1 (en) 2018-02-01
TR201900071T4 (tr) 2019-01-21
FI4005588T3 (fi) 2024-05-15
US20140329748A1 (en) 2014-11-06
US20250302923A1 (en) 2025-10-02
PT3756681T (pt) 2023-07-25
PT2821080T (pt) 2018-12-17
EP3756681A1 (en) 2020-12-30
SI2741763T1 (sl) 2016-02-29
PL3195875T3 (pl) 2019-01-31
CA2844282A1 (en) 2013-02-14
JP2020147600A (ja) 2020-09-17
AR087476A1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
MX2024008826A (es) Composicion para la estimulacion ovarica controlada.
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2021002900A (es) Composicion con complejos de nanoparticulas/anticuerpos de paclitaxel unidos a albumina para usarse al tratar linfoma.
UA116981C2 (uk) Сполуки для лікування спінальної м'язової атрофії
PH12014500904B1 (en) Antibody formulations and methods
MX360774B (es) Antagonistas de progesterona.
PH12015501088A1 (en) Dimeric compounds
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX365403B (es) Peptidos y metodos para usarlos.
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
AU2012240388A8 (en) Treatment regimens
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX388587B (es) Procedimiento para la preparacion de 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций
IN2013CH00453A (es)
UA103980C2 (ru) Способ консервативного лечения апоплексии яичника с минимальным гемоперитонеумом

Legal Events

Date Code Title Description
FG Grant or registration